Our patients can schedule a COVID-19 vaccination through NYU Langone Health MyChart or the NYU Langone Health app. Learn more about the COVID-19 vaccine. Read our updated information about wearing a mask for your visit, and our visitor policy.

If you need help accessing our website, call 855-698-9991
Skip to main content
Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.

Alec S. Goldenberg, MD

Affiliated Provider
Affiliated providers provide medical care at an NYU Langone location or a private practice, and are not employed by NYU Langone Health.
  • Specialties: Medical Oncology, Hematology
  • Treats: Adults
  • Language: English
  • Phone: 212-689-6791
View Locations

Conditions and Treatments

For Adults
Conditions
  • abdominal tumor
  • aids-related lymphoma
  • aids-related malignancies
  • anemia
  • blood cancer
  • breast cancer
  • colorectal cancer
  • gastrointestinal cancer
  • kaposi sarcoma
  • lung cancer
  • lung carcinoma
  • lymphoma
  • malignant mesothelioma
  • mediastinal tumor
  • mesothelioma
  • non-small cell lung cancer
  • platelet disorder
  • small cell lung cancer
  • solitary fibrous tumor
  • thoracic cancer
  • thymus cancer
View All Conditions and Treatments
Learn more about conditions we treat at NYU Langone:
Liver Cancer & Liver Metastases , Stomach Cancer , AIDS-Related Lymphoma , Acute Lymphoblastic Leukemia , Acute Myeloid Leukemia , Chronic Lymphocytic Leukemia , Chronic Myelogenous Leukemia , Cutaneous T-Cell Lymphoma , Hairy Cell Leukemia , Myelodysplastic Syndromes , Myeloproliferative Disorders , Non-Hodgkin Lymphoma , Breast Cancer , Male Breast Cancer , Colorectal Cancer , Small Intestine Cancer , Kaposi Sarcoma , Lung Cancer , Non-Small Cell Lung Cancer , Small Cell Lung Cancer , Hodgkin Lymphoma , Primary Central Nervous System Lymphoma , Malignant Mesothelioma , Soft Tissue Sarcoma

Positions
Board Certifications
  • American Board of Internal Medicine (Medical Oncology), 1987
  • American Board of Internal Medicine - Internal Medicine, 1986
Education and Training
  • Fellowship, Memorial Sloan Kettering Cancer Center, Hematology/Oncology, 1988
  • MD from Johns Hopkins University, 1980

Is this your profile?

Edit profile

This provider accepts the following insurance plans.

  • Aetna
     
    • Aetna HMO
    • Aetna Indemnity
    • Aetna Medicare
    • Aetna POS
    • Aetna PPO/EPO
  • Cigna
     
    • Cigna EPO/POS
    • Cigna PPO
  • Empire Blue Cross Blue Shield
     
    • Empire Blue Cross Blue Shield EPO
    • Empire Blue Cross Blue Shield HMO
    • Empire Blue Cross Blue Shield Indemnity
    • Empire Blue Cross Blue Shield MediBlue
    • Empire Blue Cross Blue Shield POS
    • Empire Blue Cross Blue Shield PPO
    • Empire Blue Cross Blue Shield Pathways, Enhanced
  • GHI
     
    • GHI CBP
  • UHC
     
    • UnitedHealthcare EPO
    • UnitedHealthcare HMO
    • UnitedHealthcare Medicare
    • UnitedHealthcare POS
    • UnitedHealthcare PPO
    • UnitedHealthcare Top Tier
  • UPN
     
    • UPN Elite
View All Accepted Plans This list of insurances changes regularly, and insurance plans listed may not be accepted at all office locations for this provider. Before your appointment, please confirm with your insurance company that this provider accepts your insurance.

Locations and Appointments

Manhattan Hematology Oncology Associates

157 East 32nd Street, 2nd Floor, New York, NY 10016

View Map
Phone

212-689-6791

Fax

212-689-7059

Interests

hematologic abnormalities, Early and advanced cancer types , mycobacterial infections, hematologic growth factors

These focus areas and their associated publications are derived from PubMed and the MeSH term library. *
represents one publication
Loading...
*Due to PubMed processing times, the most recent publications may not be reflected in the timeline.

  • Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).

    Lee, Hun Ju; Choi, Michael Y.; Siddiqi, Tanya; Wierda, William G.; Claudia Barrientos, Jacqueline; Lamanna, Nicole; Goldenberg, Alec; Isufi, Iris; Tuscano, Joseph M.; Subbiah, Suki; Weihe, Elizabeth Kristine; Ianopulos, Xen; Breitmeyer, James Bradley; Hsu, Frank J.; Wang, Michael; Jamieson, Catriona Hm; Kipps, Thomas J.

    Journal of clinical oncology. 2020; 38(15):

  • Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

    Lee, Hun Ju; Choi, Michael Y.; Siddiqi, Tanya; Wierda, William G.; Barrientos, Jacqueline C.; Lamanna, Nicole; Goldenberg, Alec; Isufi, Iris; Tuscano, Joseph; Subbiah, Suki; Koff, Jean L.; Leslie, Lori A.; Chung, Gina G.; Weihe, Elizabeth K.; Ianopulos, Xen; Breitmeyer, James B.; Hsu, Frank J.; Wang, Michael; Jamieson, Catriona; Kipps, Thomas J.

    Blood. 2020; 136:

  • Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL

    Choi, Michael Y.; Ghia, Emanuela M.; Siddiqi, Tanya; Wierda, William G.; Lee, Hun Ju; Barrientos, Jacqueline C.; Lamanna, Nicole; Goldenberg, Alec; Tzachanis, Dimitrios; Reid, Erin G.; Weihe, Elizabeth K.; Rassenti, Laura Z.; Isufi, Iris; Bieler, Stewart; Ianopulos, Xen; Breitmeyer, James B.; Jamieson, Catriona; Kipps, Thomas J.

    Blood. 2019; 134:

Read All Publications (88)